Overwhelming Majority of Voters Express Alarm Over Medicare Lab Payment Cuts Impacting Patient Care
A recent national survey conducted by Quest Diagnostics sheds light on the increasing concern among American voters regarding upcoming Medicare payment cuts to diagnostic laboratory tests. With nearly 90% of the registered voters expressing anxiety about these potential reductions, the results illustrate a widespread reliance on diagnostic testing in guiding healthcare decisions.
The survey, which involved 1,024 registered voters, revealed that 83% of respondents had relied on a diagnostic lab test in the past two years. This testing is considered essential by 96% of those surveyed, who believe it's key to the healthcare of themselves and their families, with 75% classifying it as "very important."
A troubling observation from the survey shows that voters are particularly apprehensive about the impact that cuts might have on vulnerable populations, including Medicare seniors, rural communities, and individuals managing chronic illnesses such as cancer. Approximately 50% of voters fear these groups will suffer the most from the proposed payment reductions.
These concerns are heightened by the details surrounding the historical setting of Medicare laboratory payment rates, established by the Protecting Access to Medicare Act (PAMA) of 2014. Initially intended to reflect the market rates for clinical laboratory services, PAMA's implementation did not achieve its goals. The Clinical Lab Fee Schedule (CLFS) was based on data that represented less than one percent of all laboratories, leading to artificially low payment rates that have resulted in a combined loss of nearly $4 billion from the CLFS between 2018 and 2020. If Congress does not take action, the scheduled cuts set to begin on January 1, 2027, could result in up to a 15% reduction in payment rates. Further cuts are anticipated for the following two years.
The survey highlights a strong desire for congressional intervention, with 88% of respondents expressing concern that low Medicare lab payment rates would directly impact patient access to necessary laboratory tests. The support for legislative action has broad bipartisan representation, with 75% agreement from Republicans, Democrats, and Independents on the need for immediate congressional action to prevent cuts.
The RESULTS Act—a bipartisan bill backed by approximately 130 congressional sponsors—aims to create more stable and representative Medicare payment rates for laboratory services. This act would help ensure access to comprehensive private payor data and establish protective measures against destabilizing rate cuts. Notably, the coalition backing the bill includes over 70 medical and patient advocacy organizations, demonstrating substantial support across the healthcare community.
Healthcare stakeholders have articulated the critical nature of laboratory insights in modern medicine. Lee H. Hilborne, MD, MPH, the Senior National Medical Director at Quest Diagnostics, emphasized that diagnostic lab tests are often the first line of defense in identifying health conditions. Voters recognize this essential role and understand the potential repercussions that cuts could have on timely access to needed healthcare solutions.
As the debate over Medicare lab payment cuts continues, Quest Diagnostics, in conjunction with the American Clinical Laboratory Association (ACLA), is urging Congress to pass the RESULTS Act before the imminent cuts take effect. With the vocal support for this legislative action, advocates are hopeful for a resolution that ensures ongoing access to diagnostic laboratory services for all patients.
Detailed insights and findings from this survey can be found in the report, "Left Out, Left Behind: Who's Harmed by Medicare Lab Payment Cuts?" For those looking to advocate for the passage of the RESULTS Act, additional information is available at www.StopLabCuts.org.
Overall, as voters continue to voice their concerns about the implications of Medicare lab payment reductions, it is clear that action must be taken to safeguard patient care and uphold the standards of healthcare delivery across the nation.
The survey, which involved 1,024 registered voters, revealed that 83% of respondents had relied on a diagnostic lab test in the past two years. This testing is considered essential by 96% of those surveyed, who believe it's key to the healthcare of themselves and their families, with 75% classifying it as "very important."
A troubling observation from the survey shows that voters are particularly apprehensive about the impact that cuts might have on vulnerable populations, including Medicare seniors, rural communities, and individuals managing chronic illnesses such as cancer. Approximately 50% of voters fear these groups will suffer the most from the proposed payment reductions.
These concerns are heightened by the details surrounding the historical setting of Medicare laboratory payment rates, established by the Protecting Access to Medicare Act (PAMA) of 2014. Initially intended to reflect the market rates for clinical laboratory services, PAMA's implementation did not achieve its goals. The Clinical Lab Fee Schedule (CLFS) was based on data that represented less than one percent of all laboratories, leading to artificially low payment rates that have resulted in a combined loss of nearly $4 billion from the CLFS between 2018 and 2020. If Congress does not take action, the scheduled cuts set to begin on January 1, 2027, could result in up to a 15% reduction in payment rates. Further cuts are anticipated for the following two years.
The survey highlights a strong desire for congressional intervention, with 88% of respondents expressing concern that low Medicare lab payment rates would directly impact patient access to necessary laboratory tests. The support for legislative action has broad bipartisan representation, with 75% agreement from Republicans, Democrats, and Independents on the need for immediate congressional action to prevent cuts.
The RESULTS Act—a bipartisan bill backed by approximately 130 congressional sponsors—aims to create more stable and representative Medicare payment rates for laboratory services. This act would help ensure access to comprehensive private payor data and establish protective measures against destabilizing rate cuts. Notably, the coalition backing the bill includes over 70 medical and patient advocacy organizations, demonstrating substantial support across the healthcare community.
Healthcare stakeholders have articulated the critical nature of laboratory insights in modern medicine. Lee H. Hilborne, MD, MPH, the Senior National Medical Director at Quest Diagnostics, emphasized that diagnostic lab tests are often the first line of defense in identifying health conditions. Voters recognize this essential role and understand the potential repercussions that cuts could have on timely access to needed healthcare solutions.
As the debate over Medicare lab payment cuts continues, Quest Diagnostics, in conjunction with the American Clinical Laboratory Association (ACLA), is urging Congress to pass the RESULTS Act before the imminent cuts take effect. With the vocal support for this legislative action, advocates are hopeful for a resolution that ensures ongoing access to diagnostic laboratory services for all patients.
Detailed insights and findings from this survey can be found in the report, "Left Out, Left Behind: Who's Harmed by Medicare Lab Payment Cuts?" For those looking to advocate for the passage of the RESULTS Act, additional information is available at www.StopLabCuts.org.
Overall, as voters continue to voice their concerns about the implications of Medicare lab payment reductions, it is clear that action must be taken to safeguard patient care and uphold the standards of healthcare delivery across the nation.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.